Cordia myxa, a medicinal plant recognized for its antibacterial, anti-inflammatory, antioxidant, and antidiabetic properties, is being investigated for its potential in treating malaria.

Malaria, caused by Plasmodium parasites transmitted through Anopheles mosquito bites, continues to pose a significant global health challenge.

The study employs network pharmacology to identify the active components of C. myxa and elucidate their therapeutic mechanisms against malaria.

Functional enrichment analysis reveals that the targets of C. myxa are involved in various biological processes and signaling pathways relevant to malaria treatment.

Highlighted active compounds from C. myxa, including cosmosiin, stigmastanol, robinetin, and quercetin, demonstrate the ability to regulate IL6 and CASP3, indicating their potential as malaria therapeutics.

Machine learning techniques were utilized to predict the anti-malarial activity of C. myxa compounds, assessing ten compounds against existing malaria drugs.

Molecular docking and dynamics simulations confirm the stability of interactions between these compounds and their targets.

The research utilizes databases such as SwissADME and GeneCards for target gene identification and pharmacokinetic profiling of C. myxa compounds.

The findings suggest that C. myxa could serve as a viable source for developing new anti-malarial drugs, enhancing the understanding of its medicinal properties.

However, the study underscores the necessity for further in vivo and in vitro studies to fully evaluate the safety and efficacy of C. myxa in treating malaria.